Advertisement

Guillain-Barré Syndrome

  • Yhojan Rodríguez
  • Christopher Chang
  • Diana C. González-Bravo
  • M. Eric GershwinEmail author
  • Juan-Manuel Anaya
Chapter
Part of the Contemporary Clinical Neuroscience book series (CCNE)

Abstract

Guillain-Barré syndrome (GBS) is an autoimmune acute peripheral polyneuropathy, which often follows an infectious process. The most common microorganisms associated with GBS are the bacteria Campylobacter jejuni and Mycoplasma pneumoniae. Viruses such as cytomegalovirus and the Zika virus have also been associated with GBS. The incidence of GBS ranges between 0.5 and 2 cases per 100,000 population per year. The pathophysiology of GBS most likely involves molecular mimicry, in which an autoantibody against a microorganism cross-reacts with host molecules, such as GD1a, GM1, and GM1/GD1 complex located at the terminal nerves and anterior roots, and GQ1b located on oculomotor nerves and primary sensory neurons. The classical complement system has also been implicated in facilitating the development of GBS. GBS usually presents with numbness, paresthesia, and progressive weakness, but there are several clinical variants, including acute motor axonal neuropathy (AMAN), acute inflammatory demyelinating polyneuropathy (AIDP), acute motor and sensory axonal neuropathy (AMSAM), Miller-Fisher syndrome (MFS), a pharyngeal-cervical-brachial variant, a paraparetic variant, and others. Treatment of GBS mostly targets the immune response through the use of IVIg, plasma exchange, and other forms of immunomodulatory therapy.

Keywords

Guillain-Barré syndrome Acute motor axonal neuropathy Acute inflammatory demyelinating polyneuropathy Genetics Major histocompatibility complex Molecular mimicry Complement Immunotherapy Intravenous immunoglobulins Plasma exchange 

References

  1. 1.
    Winner SJ, Evans JG. Age-specific incidence of Guillain-Barre syndrome in Oxfordshire. Q J Med. 1990;77:1297–304.PubMedCrossRefGoogle Scholar
  2. 2.
    Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol. 2009;155:1–15.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Chalela JA. Pearls and pitfalls in the intensive care management of Guillain-Barre syndrome. Semin Neurol. 2001;21:399–405.PubMedCrossRefGoogle Scholar
  4. 4.
    Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barre and Miller fisher syndromes. Pract Neurol. 2015;15:90–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Restrepo-Jimenez P, Rodriguez Y, Gonzalez P, Chang C, Gershwin ME, Anaya J-M. The immunotherapy of Guillain-Barre syndrome. Expert Opin Biol Ther. 2018;18:619–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand. 2004;110:100–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology. 2000;54:620–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Govoni V, Granieri E, Manconi M, Capone J, Casetta I. Is there a decrease in Guillain-Barre syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the local Health District of Ferrara, Italy. J Neurol Sci. 2003;216:99–103.PubMedCrossRefGoogle Scholar
  9. 9.
    Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barre syndrome. Am J Epidemiol. 1998;147:69–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barre syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr. 1994;124:220–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Dias-Tosta E, Kuckelhaus CS. Guillain Barre syndrome in a population less than 15 years old in Brazil. Arq Neuropsiquiatr. 2002;60:367–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Hart DE, Rojas LA, Rosario JA, Recalde H, Roman GC. Childhood Guillain-Barre syndrome in Paraguay, 1990 to 1991. Ann Neurol. 1994;36:859–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Olive JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barre syndrome in children <15 years of age in Latin America. J Infect Dis. 1997;175(Suppl):S160–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Molinero MR, Varon D, Holden KR, Sladky JT, Molina IB, Cleaves F. Epidemiology of childhood Guillain-Barre syndrome as a cause of acute flaccid paralysis in Honduras: 1989-1999. J Child Neurol. 2003;18:741–7.PubMedCrossRefGoogle Scholar
  15. 15.
    McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009;32:150–63.PubMedCrossRefGoogle Scholar
  16. 16.
    van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7:939–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC, Anaya J-M. Guillain-Barre syndrome in Colombia: where do we stand now? Immunol Res. 2017;65:72–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Dourado ME, Felix RH, da Silva WKA, Queiroz JW, Jeronimo SMB. Clinical characteristics of Guillain-Barre syndrome in a tropical country: a Brazilian experience. Acta Neurol Scand. 2012;125:47–53.PubMedCrossRefGoogle Scholar
  19. 19.
    McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.CrossRefGoogle Scholar
  21. 21.
    Yamamoto K, Sobue G, Iwase S, Nagamatsu M, Mano T, Mitsuma T. Skin sympathetic nerve activity in Guillain-Barre syndrome: a microneurographic study. J Neurol Neurosurg Psychiatry. 1997;63:537–41.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ropper AH, Wijdicks EFM, Truax B. Clinical features of the typical syndrome. In: Guillain-Barré Syndrome. Philadelphia; 1991. F. A Davis Company. p. 73–105.Google Scholar
  23. 23.
    Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Susuki K, Koga M, Hirata K, Isogai E, Yuki N. A Guillain-Barre syndrome variant with prominent facial diplegia. J Neurol. 2009;256:1899–905.PubMedCrossRefGoogle Scholar
  25. 25.
    Rocha Cabrero F, Morrison EH. Miller fisher syndrome. 2018.Google Scholar
  26. 26.
    Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J. 1957;1:1384–7.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Kaslow RA, Sullivan-Bolyai JZ, Hafkin B, Schonberger LB, Kraus L, Moore MJ, Yunis E, Williams RM. HLA antigens in Guillain-Barre syndrome. Neurology. 1984;34:240–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Guo L, Wang W, Li C, Liu R, Wang G. The association between HLA typing and different subtypes of Guillain Barré syndrome. Zhonghua nei ke za zhi. 2002;41:381–3. Chinese.PubMedGoogle Scholar
  29. 29.
    Magira EE, Papaioakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM, Monos DS. Differential distribution of HLA-DQ /DR epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ epitopes associated with susceptibility to and pro. J Immunol. 2003;170:3074–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Hasan ZN, Zalzala HH, Mohammedsalih HR, Mahdi BM, Abid LA, Shakir ZN, Fadhel MJ. Association between human leukocyte antigen-DR and demylinating Guillain-Barre syndrome. Neurosci. 2014;19:301–5.Google Scholar
  31. 31.
    Fekih-Mrissa N, Mrad M, Riahi A, Sayeh A, Zaouali J, Gritli N, Mrissa R. Association of HLA-DR/DQ polymorphisms with Guillain-Barré syndrome in Tunisian patients. Clin Neurol Neurosurg. 2014;121:19–22.PubMedCrossRefGoogle Scholar
  32. 32.
    Ma JJ, Nishimura M, Mine H, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome. Neurology. 1998;51:379–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Monos DS, Papaioakim M, Ho TW, Li CY, McKhann GM. Differential distribution of HLA alleles in two forms of Guillain-Barre syndrome. J Infect Dis. 1997;  https://doi.org/10.1086/513786.PubMedCrossRefGoogle Scholar
  34. 34.
    Gorodezky C, Varela B, Castro-Escobar LE, Chávez-Negrete A, Escobar-Gutiérrez A, Martínez-Mata J. HLA-DR antigens in Mexican patients with Guillain-Barré syndrome. J Neuroimmunol. 1983;4:1–7.PubMedCrossRefGoogle Scholar
  35. 35.
    McCombe PA, Clark P, Frith JA, Hammond SR, Stewart GJ, Pollard JD, McLeod JG. Alpha-1 antitrypsin phenotypes in demyelinating disease: an association between demyelinating disease and the allele PiM3. Ann Neurol. 1985;18:514–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Caporale CM, Papola F, Fioroni MA, Aureli A, Giovannini A, Notturno F, Adorno D, Caporale V, Uncini A. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol. 2006;177:112–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. J Neuroimmunol. 2005;161:183–9.PubMedCrossRefGoogle Scholar
  38. 38.
    van Sorge NM, van der Pol W-L, Jansen MD, et al. Severity of Guillain-Barre syndrome is associated with fc gamma receptor III polymorphisms. J Neuroimmunol. 2005;162:157–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Blum S, Csurhes P, Reddel S, Spies J, McCombe P. Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré syndrome. J Neuroimmunol. 2014;267:92–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Vedeler CA, Raknes G, Myhr KM, Nyland H. IgG fc-receptor polymorphisms in Guillain-Barre syndrome. Neurology. 2000;55:705–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Sang D, Chen Q, Liu X, Qu H, Wei D, Yin L, Zhang L. Fc receptor like 3 in Chinese patients of Han nationality with Guillain-Barre syndrome. J Neuroimmunol. 2012;246:65–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Dekker MJHJ, van den Akker ELT, Koper JW, et al. Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barre syndrome. J Peripher Nerv Syst. 2009;14:75–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Feeney DJ, Pollard JD, McLeod JG, Stewart GJ, De Lange GG. Gm haplotypes in inflammatory demyelinating polyneuropathies. Ann Neurol. 1989;26:790–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Myhr K-M, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with Guillain-Barre syndrome. J Neuroimmunol. 2003;139:81–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Pandey JP, Koga M, Yuki N. Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barre syndrome. Neurogenetics. 2005;6:225–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA, Jacobs BC. Mannose-binding lectin contributes to the severity of Guillain-Barre syndrome. J Immunol. 2006;177:4211–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Geleijns K, Emonts M, Laman JD, van Rijs W, van Doorn PA, Hermans PWM, Jacobs BC. Genetic polymorphisms of macrophage-mediators in Guillain-Barre syndrome. J Neuroimmunol. 2007;190:127–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang J, Dong H, Li B, Li C, Guo L. Association of tumor necrosis factor polymorphisms with Guillain-Barre syndrome. Eur Neurol. 2007;58:21–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Prasad KN, Nyati KK, Verma A, Rizwan A, Paliwal VK. Tumor necrosis factor-alpha polymorphisms and expression in Guillain-Barre syndrome. Hum Immunol. 2010;71:905–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Yuki N, Sato S, Tsuji S, Ogawa K, Miyatake T. Human leukocyte antigens in Fisher’s syndrome. Ann Neurol. 1993;33:655–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Jiao H, Wang W, Wang H, Wu Y, Wang L. Tumor necrosis factor alpha 308 G/a polymorphism and Guillain-Barre syndrome risk. Mol Biol Rep. 2012;39:1537–40.PubMedCrossRefGoogle Scholar
  52. 52.
    Nyati KK, Prasad KN, Verma A, Singh AK, Rizwan A, Sinha S, Paliwal VK, Pradhan S. Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barre syndrome in northern Indian population. J Neuroimmunol. 2010;218:116–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Yuki N, Sato S, Itoh T, Miyatake T. HLA-B35 and acute axonal polyneuropathy following campylobacter infection. Neurology. 1991;41:1561–3.PubMedCrossRefGoogle Scholar
  54. 54.
    Hafez M, Nagaty M, Al-Tonbary Y, El-Shennawy FA, El-Mongui A, El-Sallab S, Attia S. HLA-antigens in Guillain-Barre syndrome. J Neurogenet. 1985;2:285–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Li H, Yuan J, Hao H, Yan Z, Wang S. HLA alleles in patients with Guillain-Barre syndrome. Chin Med J. 2000;113:429–32.PubMedGoogle Scholar
  56. 56.
    Schirmer L, Worthington V, Solloch U, et al. Higher frequencies of HLA DQB1∗05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome. J Neurol. 2016;263:2105–13.PubMedCrossRefGoogle Scholar
  57. 57.
    Rees JH, Vaughan RW, Kondeatis E, Hughes RAC. HLA-class II alleles in Guillain-Barré syndrome and Miller fisher syndrome and their association with preceding campylobacter jejuni infection. J Neuroimmunol. 1995;62:53–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Sinha S, Prasad KN, Jain D, Nyati KK, Pradhan S, Agrawal S. Immunoglobulin IgG fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome. Acta Neurol Scand. 2010;122:21–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today. 1993;14:426–30.PubMedCrossRefGoogle Scholar
  60. 60.
    Nahata MC. Ophthalmoplegia following enteric fever. J Indian Med Assoc. 1961;37:134–5.PubMedGoogle Scholar
  61. 61.
    Nager F, Regli F. Polyneuritis with flaccid tetraplegia in typhoid fever. Schweiz Med Wochenschr. 1963;93:1030–3. German.PubMedGoogle Scholar
  62. 62.
    Massei F, Gori L, Taddeucci G, Macchia P, Maggiore G. Bartonella henselae infection associated with Guillain-Barre syndrome. Pediatr Infect Dis J. 2006;25:90–1.PubMedCrossRefGoogle Scholar
  63. 63.
    Carman KB, Yimenicioglu S, Ekici A, Yakut A, Dinleyici EC. Co-existence of acute transverse myelitis and Guillain–Barré syndrome associated with Bartonella henselae infection. Paediatr Int Child Health. 2013;33:190–2.PubMedCrossRefGoogle Scholar
  64. 64.
    Kountouras J, Zavos C, Deretzi G, Gavalas E, Polyzos S, Vardaka E, Kountouras C, Giartza-Taxidou E, Koutlas E, Tsiptsios I. Helicobacter pylori may play an important role in both axonal type Guillain-Barré syndrome and acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurol Neurosurg. 2011;113:520.PubMedCrossRefGoogle Scholar
  65. 65.
    Kountouras J, Deretzi G, Zavos C, Karatzoglou P, Touloumis L, Nicolaides T, Chatzopoulos D, Venizelos I. Association between helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2005;12:139–43.PubMedCrossRefGoogle Scholar
  66. 66.
    Von Linstow ML, Andersen J. Guillain-Barré syndrome associated to infection with Borrelia burgdorferi: a case report. J Pediatr Infect Dis. 2007;2:247–50.Google Scholar
  67. 67.
    Durovska J, Bazovska S, Pancak J, Zaborska M, Derdakova M, Traubner P. Infection with B. Burgdorferi s.L., and the CNS demyelinating disease. A case report. Neuro Endocrinol Lett. 2011;32:411–4.PubMedGoogle Scholar
  68. 68.
    Shapiro EE. Guillain-Barre syndrome in a child with serologic evidence of Borrelia burgdorferi infection. Pediatr Infect Dis J. 1998;17:264–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Bouma PA, Carpay HA, Rijpkema SG. Antibodies to Borrelia burgdorferi in Guillain-Barré syndrome. Lancet. 1989;2:739.PubMedCrossRefGoogle Scholar
  70. 70.
    Patel K, Shah S, Subedi D. Clinical association: Lyme disease and Guillain-Barre syndrome. Am J Emerg Med. 2017;  https://doi.org/10.1016/j.ajem.2017.07.030.PubMedCrossRefGoogle Scholar
  71. 71.
    Stadsvold C. Guillain-Barré syndrome in the setting of acute CNS Lyme disease: a case report. PM&R. 2010;2:S113.CrossRefGoogle Scholar
  72. 72.
    Samantray SK, Johnson SC, Mathai KV, Pulimood BM. Landry-Guillain-Barre-Strohl syndrome. A study of 302 cases. Med J Aust. 1977;2:84–91.PubMedGoogle Scholar
  73. 73.
    Toerner JG, Kumar PN, Garagusi VF. Guillain-Barré syndrome associated with Rocky Mountain spotted fever: case report and review. Clin Infect Dis. 1996;22:1090–1.PubMedCrossRefGoogle Scholar
  74. 74.
    de Galan BE, van Kasteren BJ, van den Wall Bake AW, Vreugdenhil G. A case of Guillain-Barré syndrome due to infection with rickettsia conorii. Eur J Clin Microbiol Infect Dis. 1999;18:79–80.PubMedGoogle Scholar
  75. 75.
    Evangelista T, Pimentel J, Luis Mde L. Acute polyradiculoneuritis associated with boutonneuse fever. Acta Medica Port. 1994;7:437–9. PortugueseGoogle Scholar
  76. 76.
    Popivanova N, Hristova D, Hadjipetrova E. Guillain-Barré polyneuropathy associated with mediterranean spotted fever: case report. Clin Infect Dis. 1998;27:1549.PubMedCrossRefGoogle Scholar
  77. 77.
    Zhu H, Arukala V, Sheikh S, Uprety A, McCrary D, Silverman T, Cranston H. Human monocytic ehrlichiosis presenting as guillain-Barre syndrome. Neurology. 2017;88:P3.315.Google Scholar
  78. 78.
    Grapperon AM, Wybrecht D, Pons S, Landais C, Alla P, Faivre A. Guillain-Barré syndrome heralding acute query fever. Rev Neurol (Paris). 2013;169:269–74. French.CrossRefGoogle Scholar
  79. 79.
    Mushinski JF, Taniguchi RM, Stiefel JW. Guillain-Barre syndrome associated with Ulceroglandular Tularemia. Neurology. 1964;14:877–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Syrjälä H, Kujala P, Myllylä V, Koskela P. Guillain-barré syndrome and tularemia pleuritis with high adenosine deaminase activity in pleural fluid. Infection. 1989;17:152–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Ylipalosaari P, Ala-Kokko TI, Tuominen H, Syrjälä H. Guillain–Barré syndrome and ulceroglandular tularemia. Infection. 2013;41:881–3.PubMedCrossRefGoogle Scholar
  82. 82.
    Osuntokun BO, Bademosi O, Ogunremi K, et al. Neuropsychiatric manifestations of typhoid fever in 959 patients. Arch Neurol. 1972;27:7–13.PubMedCrossRefGoogle Scholar
  83. 83.
    Khan FY, Kamha AA, Abbas MT, Miyares F, Elshafie SS. Guillain-Barré syndrome associated with salmonella paratyphi a. Clin Neurol Neurosurg. 2007;109:452–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Namiduru M, Karaoglan I, Yilmaz M. Guillain-Barré syndrome associated with acute neurobrucellosis. Int J Clin Pract. 2003;57:919–20.PubMedGoogle Scholar
  85. 85.
    Marzetti S, Carranza C, Roncallo M, Escobar GI, Lucero NE. Recent trends in human Brucella canis infection. Comp Immunol Microbiol Infect Dis. 2013;36:55–61.PubMedCrossRefGoogle Scholar
  86. 86.
    Al-Eissa YA, Al-Herbish AS. Severe hypertension: an unusual presentation of Guillain-Barre syndrome in a child with brucellosis. Eur J Pediatr. 1996;155:53–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Watanabe K, Kim S, Nishiguchi M, Suzuki H, Watarai M. Brucella melitensis infection associated with Guillain-Barré syndrome through molecular mimicry of host structures. FEMS Immunol Med Microbiol. 2005;45:121–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Babamahmoodi A, Babamahmoodi F. Brucellosis, presenting with Guillain-Barré syndrome. J Glob Infect Dis. 2011;3:390.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Pollard JD, Baverstock J, McLeod JG. Class II antigen expression and inflammatory cells in the Guillain-Barre syndrome. Ann Neurol. 1987;21:337–41.PubMedCrossRefGoogle Scholar
  90. 90.
    Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O’Brien SJ. Incidence of Guillain-Barre syndrome among patients with campylobacter infection: a general practice research database study. J Infect Dis. 2006;194:95–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Phongsisay V. The immunobiology of campylobacter jejuni: innate immunity and autoimmune diseases. Immunobiology. 2016;221:535–43.PubMedCrossRefGoogle Scholar
  92. 92.
    Varki A, Cummings RD, Esko JD, et al. Essentials of glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2015.Google Scholar
  93. 93.
    Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve. 2007;35:691–711.PubMedCrossRefGoogle Scholar
  94. 94.
    Godschalk PCR, Heikema AP, Gilbert M, et al. The crucial role of campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J Clin Invest. 2004;114:1659–65.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Phongsisay V, Perera VN, Fry BN. Exchange of Lipooligosaccharide synthesis genes creates potential Guillain-Barré syndrome-inducible strains of campylobacter jejuni. Infect Immun. 2006;74:1368–72.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Koga M, Yuki N. Campylobacter jejuni cst-II polymorphisms and association with development of Guillain-Barre syndrome. Neurology. 2007;69:1727–8; author reply 1728PubMedCrossRefGoogle Scholar
  97. 97.
    Nachamkin I, Liu J, Li M, Ung H, Moran AP, Prendergast MM, Sheikh K. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun. 2002;70:5299–303.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Gilbert M, Karwaski M-F, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham A-M, Wakarchuk WW. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem. 2002;277:327–37.PubMedCrossRefGoogle Scholar
  99. 99.
    Susuki K, Odaka M, Mori M, Hirata K, Yuki N. Acute motor axonal neuropathy after mycoplasma infection: evidence of molecular mimicry. Neurology. 2004;62:949–56.PubMedCrossRefGoogle Scholar
  100. 100.
    Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve. 1995;18:409–13.PubMedCrossRefGoogle Scholar
  101. 101.
    Kusunoki S, Shiina M, Kanazawa I. Anti-gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology. 2001;57:736–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H. Association of anti-GM2 antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection. J Neuroimmunol. 1996;68:19–26.PubMedCrossRefGoogle Scholar
  103. 103.
    Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. Guillain-Barre syndrome with IgM antibody to the ganglioside GalNAc-GD1a. J Neuroimmunol. 2001;113:260–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Britt W. Virus entry into host, establishment of infection, spread in host, mechanisms of tissue damage. 2007.Google Scholar
  105. 105.
    Tsukaguchi M, Tagawa Y, Takeuchi H, Yuki N. IgM anti-GM2 antibody in a patient with Guillain-Barre syndrome subsequent to cytomegalovirus hepatitis cross reacts with N-acetylgalactosaminyl GD1a. J Neurol Neurosurg Psychiatry. 1998;65:407–8.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Penner E, Maida E, Mamoli B, Gangl A. Serum and cerebrospinal fluid immune complexes containing hepatitis B surface antigen in Guillain-Barre syndrome. Gastroenterology. 1982;82:576–80.PubMedGoogle Scholar
  107. 107.
    Lucchese G, Kanduc D. Zika virus and autoimmunity: from mycrocephaly to Guillain-Barré syndrome, and beyond. Autoimmun Rev. 2016;15:801–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Lu M-O, Zhu J. The role of cytokines in Guillain-Barre syndrome. J Neurol. 2011;258:533–48.PubMedCrossRefGoogle Scholar
  109. 109.
    Monaco S, Gehrmann J, Raivich G, Kreutzberg GW. MHC-positive, ramified macrophages in the normal and injured rat peripheral nervous system. J Neurocytol. 1992;21:623–34.PubMedCrossRefGoogle Scholar
  110. 110.
    Zhang H-L, Zheng X-Y, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev. 2013;24:443–53.PubMedCrossRefGoogle Scholar
  111. 111.
    Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol. 2001;64:109–27.PubMedCrossRefGoogle Scholar
  112. 112.
    Zhang H-L, Hassan MY, Zheng X-Y, Azimullah S, Quezada HC, Amir N, Elwasila M, Mix E, Adem A, Zhu J. Attenuated EAN in TNF-alpha deficient mice is associated with an altered balance of M1/M2 macrophages. PLoS One. 2012;7:e38157.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR. Guillain-Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118(Pt 3):577–95.PubMedCrossRefGoogle Scholar
  114. 114.
    Prineas JW. Pathology of the Guillain-Barre syndrome. Ann Neurol. 1981;9(Suppl):6–19.PubMedCrossRefGoogle Scholar
  115. 115.
    Kiefer R, Kieseier BC, Bruck W, Hartung HP, Toyka KV. Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain. 1998;121(Pt 3):469–79.PubMedCrossRefGoogle Scholar
  116. 116.
    Zettl UK, Gold R, Hartung HP, Toyka KV. Apoptotic cell death of T-lymphocytes in experimental autoimmune neuritis of the Lewis rat. Neurosci Lett. 1994;176:75–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Zhu J, Bai XF, Mix E, Link H. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin. Clin Immunol Immunopathol. 1997;84:85–94.PubMedCrossRefGoogle Scholar
  118. 118.
    Willison HJ, Halstead SK, Beveridge E, Zitman FMP, Greenshields KN, Morgan BP, Plomp JJ. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barre syndrome. J Neuroimmunol. 2008;201–202:172–82.PubMedCrossRefGoogle Scholar
  119. 119.
    Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, Asbury AK, Griffin JW. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRefGoogle Scholar
  120. 120.
    Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain. 2003;126:2034–42.PubMedCrossRefGoogle Scholar
  121. 121.
    Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller fisher syndrome. J Neuroimmunol. 1994;50:159–65.PubMedCrossRefGoogle Scholar
  122. 122.
    Goodyear CS, O’Hanlon GM, Plomp JJ, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest. 1999;104:697–708.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RAG, Willison HJ. Complement inhibition abrogates nerve terminal injury in Miller fisher syndrome. Ann Neurol. 2005;58:203–10.PubMedCrossRefGoogle Scholar
  124. 124.
    Halstead SK, O’Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, Plomp JJ, Willison HJ. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–23.PubMedCrossRefGoogle Scholar
  125. 125.
    Dalakas MC. Pathophysiology of autoimmune polyneuropathies. Presse Med. 2013;42:e181–92.PubMedCrossRefGoogle Scholar
  126. 126.
    Yuki N, Hartung H-P. Guillain-Barre syndrome. N Engl J Med. 2012;366:2294–304.PubMedCrossRefGoogle Scholar
  127. 127.
    Astrom KE, Webster HD, Arnason BG. The initial lesion in experimental allergic neuritis. A phase and electron microscopic study. J Exp Med. 1968;128:469–95.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Hughes RA, Kadlubowski M, Gray IA, Leibowitz S. Immune responses in experimental allergic neuritis. J Neurol Neurosurg Psychiatry. 1981;44:565–9.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Wang F-J, Cui D, Qian W-D. Therapeutic effect of CD4+CD25+ regulatory T cells amplified in vitro on experimental autoimmune neuritis in rats. Cell Physiol Biochem. 2018;47:390–402.PubMedCrossRefGoogle Scholar
  130. 130.
    Yang M, Peyret C, Shi XQ, Siron N, Jang JH, Wu S, Fournier S, Zhang J. Evidence from human and animal studies: pathological roles of CD8(+) T cells in autoimmune peripheral neuropathies. Front Immunol. 2015;6:532.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Yang M, Shi XQ, Peyret C, Oladiran O, Wu S, Chambon J, Fournier S, Zhang J. Effector/memory CD8(+) T cells synergize with co-stimulation competent macrophages to trigger autoimmune peripheral neuropathy. Brain Behav Immun. 2018;71:142–57.PubMedCrossRefGoogle Scholar
  132. 132.
    Varki A, Sharon N. Historical background and overview. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials glycobiology. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2009. p. 1–22.Google Scholar
  133. 133.
    Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, Yuki N. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barre syndrome. J Neuroimmunol. 2008;194:181–90.PubMedCrossRefGoogle Scholar
  134. 134.
    McGonigal R, Rowan EG, Greenshields KN, Halstead SK, Humphreys PD, Rother RP, Furukawa K, Willison HJ. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain. 2010;133:1944–60.PubMedCrossRefGoogle Scholar
  135. 135.
    Lopez PH, Zhang G, Zhang J, Lehmann HC, Griffin JW, Schnaar RL, Sheikh KA. Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair. J Neurosci. 2010;30:9533–41.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Ito M, Kuwabara S, Odaka M, Misawa S, Koga M, Hirata K, Yuki N. Bickerstaff’s brainstem encephalitis and fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008;255:674–82.PubMedCrossRefGoogle Scholar
  137. 137.
    Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology. 1993;43:1911–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Liu J-X, Willison HJ, Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci. 2009;50:3226–32.PubMedCrossRefGoogle Scholar
  139. 139.
    Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. Arch Neurol. 2007;64:1519–23.PubMedCrossRefGoogle Scholar
  140. 140.
    Hahn AF, Feasby TE, Wilkie L, Lovgren D. Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve. 1993;16:1174–80.PubMedCrossRefGoogle Scholar
  141. 141.
    Saida T, Saida K, Dorfman SH, Silberberg DH, Sumner AJ, Manning MC, Lisak RP, Brown MJ. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science. 1979;204:1103–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Yako K, Kusunoki S, Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barre syndrome. J Neurol Sci. 1999;168:85–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. Guillain-Barre syndrome associated with IgG monospecific to ganglioside GD1b. Neurology. 2001;56:1227–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve. 1996;19:474–87.PubMedCrossRefGoogle Scholar
  145. 145.
    Kwa MS, van Schaik IN, Brand A, Baas F, Vermeulen M. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol. 2001;116:220–5.PubMedCrossRefGoogle Scholar
  146. 146.
    Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol. 2000;104:139–46.PubMedCrossRefGoogle Scholar
  147. 147.
    Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain. 2009;132:260–73.PubMedCrossRefGoogle Scholar
  148. 148.
    Novakovic SD, Levinson SR, Schachner M, Shrager P. Disruption and reorganization of sodium channels in experimental allergic neuritis. Muscle Nerve. 1998;21:1019–32.PubMedCrossRefGoogle Scholar
  149. 149.
    Kaida K, Kusunoki S. Guillain-Barre syndrome: update on immunobiology and treatment. Expert Rev Neurother. 2009;9:1307–19.PubMedCrossRefGoogle Scholar
  150. 150.
    van Doorn P. Acute flaccid paralysis. Contin Lifelong Learn Neurol. 2003;9.Google Scholar
  151. 151.
    Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barre syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123:1487–95.PubMedCrossRefGoogle Scholar
  152. 152.
    Telleman JA, Grimm A, Goedee S, Visser LH, Zaidman CM. Nerve ultrasound in polyneuropathies. Muscle Nerve. 2018;57:716–28.PubMedCrossRefGoogle Scholar
  153. 153.
    Mori A, Nodera H, Takamatsu N, Maruyama-Saladini K, Osaki Y, Shimatani Y, Kaji R. Sonographic evaluation of peripheral nerves in subtypes of Guillain-Barre syndrome. J Neurol Sci. 2016;364:154–9.PubMedCrossRefGoogle Scholar
  154. 154.
    Berciano J, Sedano MJ, Pelayo-Negro AL, Garcia A, Orizaola P, Gallardo E, Lafarga M, Berciano MT, Jacobs BC. Proximal nerve lesions in early Guillain-Barre syndrome: implications for pathogenesis and disease classification. J Neurol. 2017;264:221–36.PubMedCrossRefGoogle Scholar
  155. 155.
    Zuccoli G, Panigrahy A, Bailey A, Fitz C. Redefining the Guillain-Barre spectrum in children: neuroimaging findings of cranial nerve involvement. AJNR Am J Neuroradiol. 2011;32:639–42.PubMedCrossRefGoogle Scholar
  156. 156.
    Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S, Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2003;24(Suppl 4):S217–21.Google Scholar
  157. 157.
    Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl:2–13.CrossRefGoogle Scholar
  158. 158.
    Jacobs BC, O’Hanlon GM, Bullens RWM, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126:2220–34.PubMedCrossRefGoogle Scholar
  159. 159.
    Lehmann HC, Hartung H-P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol. 2011;231:61–9.PubMedCrossRefGoogle Scholar
  160. 160.
    Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;(7):CD002063.Google Scholar
  161. 161.
    Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya J-M, Gershwin ME. Guillain-Barre syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol. 2016;12:1175–89.PubMedCrossRefGoogle Scholar
  162. 162.
    Bouget J, Chevret S, Chastang C, Raphael JC. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, randomized, multicenter study. The French cooperative group. Crit Care Med. 1993;21:651–8.PubMedCrossRefGoogle Scholar
  163. 163.
    Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.PubMedGoogle Scholar
  164. 164.
    Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez QJH. Human immunoglobulin versus Plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. 2016;18:1–11.PubMedCrossRefGoogle Scholar
  165. 165.
    Trial, Plasma Exchange/Sandoglobulin, Guillain-Barré Syndrome, Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma exchange/Sandoglobulin Guillain-Barre syndrome trial group. Lancet (London England). 1997;349:225–30.CrossRefGoogle Scholar
  166. 166.
    Wang Y-Z, Lv H, Shi Q-G, Fan X-T, Li L, Yi Wong AH, Hao Y-L, Si C-P, Li C-L, Yuki N. Action mechanism of corticosteroids to aggravate Guillain-Barre syndrome. Sci Rep. 2015;5:13931.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Goodall JA, Kosmidis JC, Geddes AM. Effect of corticosteroids on course of Guillain-Barre syndrome. Lancet (London, England). 1974;1:524–6.CrossRefGoogle Scholar
  168. 168.
    Hughes RAC, Swan AV, Raphael J-C, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245–57.PubMedCrossRefGoogle Scholar
  169. 169.
    Hughes RAC. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat. 2002;200:331–9.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2016;10:CD001446.PubMedGoogle Scholar
  171. 171.
    Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial. Neurology. 2001;57:774–80.PubMedCrossRefGoogle Scholar
  172. 172.
    Wollinsky KH, Hulser PJ, Westarp ME, Mehrkens HH, Kornhuber HH. Cerebrospinal fluid pheresis in Guillain Barre syndrome. Med Hypotheses. 1992;38:155–65.PubMedCrossRefGoogle Scholar
  173. 173.
    Wollinsky KH, Weindler M, Hulser PJ, Geiger P, Matzek N, Mehrkens HH, Kornhuber HH. Liquorpheresis (CSF-filtration): an effective treatment in acute and chronic severe autoimmune polyradiculoneuritis (Guillain-Barre syndrome). Eur Arch Psychiatry Clin Neurosci. 1991;241:73–6.PubMedCrossRefGoogle Scholar
  174. 174.
    Pilch KS, Spaeth PJ, Yuki N, Wakerley BR. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Rev Neurother. 2017;17:579–91.PubMedCrossRefGoogle Scholar
  175. 175.
    Halstead SK, Zitman FMP, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, Rother RP, Plomp JJ, Willison HJ. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197–208.PubMedCrossRefGoogle Scholar
  176. 176.
    Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P, Willison HJ. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22:4–12.PubMedCrossRefGoogle Scholar
  177. 177.
    Hepburn NJ, Williams AS, Nunn MA, Chamberlain-Banoub JC, Hamer J, Morgan BP, Harris CL. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem. 2007;282:8292–9.PubMedCrossRefGoogle Scholar
  178. 178.
    Halstead SK, Humphreys PD, Zitman FMP, Hamer J, Plomp JJ, Willison HJ. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller fisher syndrome. J Peripher Nerv Syst. 2008;13:228–35.PubMedCrossRefGoogle Scholar
  179. 179.
    Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, Hirata K, Shinoda M, Yuki N. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101–4.PubMedCrossRefGoogle Scholar
  180. 180.
    Danielsson C, Pascual M, French L, Steiger G, Schifferli JA. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage. Eur J Immunol. 1994;24:2725–31.PubMedCrossRefGoogle Scholar
  181. 181.
    Walgaard C, Jacobs BC, van Doorn PA. Emerging drugs for Guillain-Barre syndrome. Expert Opin Emerg Drugs. 2011;16:105–20.PubMedCrossRefGoogle Scholar
  182. 182.
    Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett. 1995;200:167–70.PubMedCrossRefGoogle Scholar
  183. 183.
    Creange A. A role for interferon-beta in Guillain-Barre syndrome. BioDrugs. 2000;14:1–11.PubMedCrossRefGoogle Scholar
  184. 184.
    Zou LP, Ma DH, Wei L, van der Meide PH, Mix E, Zhu J. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J Neurosci Res. 1999;56:123–30.PubMedCrossRefGoogle Scholar
  185. 185.
    Ostronoff F, Perales M-A, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barre syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008;42:71–2.PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    FDA. Cyclophosphamide Tablets, USP. FDA. In: FDA. 2012. https://www.accessdata.fda.gov/drug%0Asatfda_docs/label/2012/012141s089lbl.pdf. Accessed 18 Oct 2018.
  187. 187.
    Rosen AD, Vastola EF. Clinical effects of cyclophosphamide in Guillain-Barre polyneuritis. J Neurol Sci. 1976;30:179–87.PubMedCrossRefGoogle Scholar
  188. 188.
    Mangano K, Dati G, Quattrocchi C, Proietti L, Mazzarino C, Di Marco R, Bendtzen K, Greco B, Zaratin P, Nicoletti F. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barre syndrome. J Neuroimmunol. 2008;196:107–15.PubMedCrossRefGoogle Scholar
  189. 189.
    Blum S, McCombe PA. Genetics of Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014;19:88–103.PubMedCrossRefGoogle Scholar
  190. 190.
    Rodriguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Monsalve DM, Gershwin ME, Anaya J-M. Guillain-Barre syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15:547–62.PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Xiao J, Simard AR, Shi F-D, Hao J. New strategies in the management of Guillain-Barre syndrome. Clin Rev Allergy Immunol. 2014;47:274–88.PubMedCrossRefGoogle Scholar
  192. 192.
    Garssen MPJ, van Koningsveld R, van Doorn PA, et al. Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry. 2007;78:1012–3.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yhojan Rodríguez
    • 1
  • Christopher Chang
    • 2
    • 3
  • Diana C. González-Bravo
    • 1
  • M. Eric Gershwin
    • 2
    Email author
  • Juan-Manuel Anaya
    • 1
  1. 1.Center for Autoimmune Diseases Research (CREA), School of Medicine and Health SciencesUniversidad del RosarioBogotaColombia
  2. 2.Division of Rheumatology, Allergy and Clinical ImmunologyUniversity of California Davis, School of MedicineDavisUSA
  3. 3.Division of Pediatric Immunology and AllergyJoe DiMaggio Children’s HospitalHollywoodUSA

Personalised recommendations